A compassionate use program of Emcitate to treat the rare genetic disease MCT8 deficiency
Latest Information Update: 22 Sep 2021
At a glance
- Drugs Tiratricol (Primary)
- Indications Allan-Herndon-Dudley syndrome
- Focus Therapeutic Use
- Sponsors Egetis Therapeutics
- 22 Sep 2021 New trial record
- 09 Sep 2021 According to an Egetis media release, it has received approval from the Turkish Medicines Agency for a compassionate use program of its leading candidate drug Emcitate to treat the rare genetic disease MCT8 deficiency.